Psychotropic practice patterns for youth: A 10-year perspective

Archives of Pediatrics and Adolescent Medicine

Volumn 157, Issue 1, 2003, Pages 17-25

  Zito, Julie Magno ^a,b   Safer, Daniel J ^c   DosReis, Susan ^c   Gardner, James F ^a   Magder, Laurence ^a   Soeken, Karen ^a   Boles, Myde ^d   Lynch, Frances ^d   Riddle, Mark A ^c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; HYDROXYZINE; HYPNOTIC SEDATIVE AGENT; LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CAUCASIAN; CHILD; CHILD PSYCHIATRY; CLINICAL PRACTICE; COMMUNITY CARE; FEMALE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL RECORD; MENTAL DISEASE; NEGRO; OUTPATIENT; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; UNITED STATES;

EID: 0037233358     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.157.1.17     Document Type: Review

References (46)

1. Dulcan M, for the American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl):85S-121S.
2. American Academy of Pediatrics, Committee on Quality Improvement Subcommittee on Attention-Deficit Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
3. US Public Health Service. Report of the Surgeon General's Conference on Children's Mental Health: A National Action Agenda. Washington, DC: Dept of Health and Human Services; 2000.
4. Lewis L. Unmet needs in diagnosis and treatment of mania and depression in children and adolescents. Biol Psychiatry. 2001;49:960-961.
5. National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2000;39:182-193.
6. Pediatric patients; regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products; proposed rule, 21 CFR §201, 312, 314, 601 (1997).
7. Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics. 2001;108:983-989.
8. Kelleher KJ, McInerny TK, Gardner WP, Childs GE, Wasserman RC. Increasing identification of psychosocial problems: 1979-1996. Pediatrics. 2000;105:1313-1321.
9. Vitiello B. Treatment algorithms in child psychopharmacology research. J Child Adolesc Psychopharmacol. 1997;7:3-8.
10. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder, I: attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:908-919.
11. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder, II: tactics. J Am Acad Child Adolesc Psychiatry. 2000;39:920-927.
12. Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry. 1999;38:557-565.
13. dosReis S, Zito JM, Safer DJ, Soeken K. Mental health services for youths in foster care and disabled youths. Am J Public Health. 2001;91:1094-1099.
14. Goodwin R, Gould MS, Blanco C, Olfson M. Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv. 2001;52:1081-1087.
15. Hong SH, Shepherd MD. Psychosocial and demographic predictors of pediatric psychotropic medication use. Am J Health Syst Pharm. 1996;53:1934-1939.
16. Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L. Multiple psychotropic pharmacotherapy in children and adolescents: a study of Connecticut Medicaid managed care enrollees. Psychiatr Serv. In press.
17. Olfson M, Marcus SC, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2002; 41:514-521.
18. Schirm E, Tobi H, Zito JM, deJong-van den Berg L. Psychotropic medication in children: a study from the Netherlands. Pediatrics [serial online]. 2001;108: e25.
19. Boles M, Lynch FL, DeBar LL. Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. J Child Adolesc Psychopharmacol. 2001;11:43-52.
20. Barnard L, Lajeunesse N. Taking a look at CNS stimulant use in Quebec children since 1995 [abstract]. Pharmacoepidemiol Drug Saf. 2001;10(suppl):S100.
21. Ivis FJ, Adlaf EM. Prevalence of methylphenidate use among adolescents in Ontario. Can J Public Health. 1999;90:309-312.
22. Rowland AS, Umbach DM, Stallone L, Bohlig EM, Sandler DP. Prevalence of medication treatment for attention deficit-hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health. 2002;92:231-234.
23. LeFever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health. 1999;89:1359-1364.
24. Rushton JL, Whitmire JT. Pediatric stimulant and SSRI prescription trends: 1992-1998. Arch Pediatr Adolesc Med. 2001;155:560-565.
25. Bussing R, Zima BT, Belin T. Variations in ADHD treatment among special education students. J Am Acad Child Adolesc Psychiatry. 1998;37:968-976.
26. Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, Fox M. Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol. 1998;8:99-105.
27. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025-1030.
28. American Society of Health-System Pharmacists. AHFS Drug Information. Bethesda, Md; American Society of Health-System Pharmacists; 1999:ix.
29. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. New York, NY: Van Nostrand Reinhold Co; 1982:297.
30. Willy ME, Manda B, Shatin D, Drinkard CR, Graham DJ. A study of compliance with FDA recommendations for pemoline (Cylert). J Am Acad Child Adolesc Psychiatry. 2002;41:785-790.
31. Zito JM, Safer DJ, dosReis S, et al. Rising prevalence of antidepressant treatments for US children and adolescents. Pediatrics. 2000;109:721-727.
32. Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry. 1996;35: 599-605.
33. Weller E, Rowan A, Elia J, Weller R. Aggressive behavior in patients with attentiondeficit/hyperactivity disorder, conduct disorder, and pervasive developmental disorders. J Clin Psychiatry. 1999;60:5-11.
34. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98:1084-1088.
35. Stein BD, Sturm R, Kapur K, Ringel J. Psychotropic medication costs among youth with private insurance in 1998. Psychiatr Serv. 2001;52:152.
36. Zito JM, Safer DJ. Antidepressant treatments in children and adolescents: bridging the gap between efficacy and effectiveness. Curr Psychiatry Rep. 2001;3: 115-125.
37. Kelleher KJ, Hohmann AA, Larson DB. Prescription of psychotropics to children in office-based practice. AJDC. 1989;143:855-859.
38. Zuvekas SH. Trends in mental health services use and spending, 1987-1996. Health Aff (Millwood). 2001;20:214-224.
39. Shaffer D, Fisher P, Dulcan MK, et al, for the Methods for the Epidemiology of Child and Adolescent Mental Disorders Study. The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates and performance in the MECA Study. J Am Acad Child Adolesc Psychiatry. 1996;35:865-877.
40. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry. 2002;59:115-123.
41. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner J, Zarin DA. Psychotherapeutic medication patterns for youths with attention deficit hyperactivity disorder. Arch Pediatr Adolesc Med. 1999;153:1257-1263.
42. Shatin D, Levin R, Ireys HT, Haller V. Health care utilization by children with chronic illnesses: a comparison of Medicaid and employer-insured managed care. Pediatrics [serial online]. 1998;102:e44.
43. Kuhlthau K, Perrin JM, Ettner SL, McLaughlin TJ, Gortmaker SL. Highexpenditure children with supplemental security income. Pediatrics. 1998;102: 610-615.
44. Horwitz SM, Owens P, Simms MD. Specialized assessments for children in foster care. Pediatrics. 2000;106:59-66.
45. dosReis S, Zito J, Safer D, Soeken K, Mitchell JW, Ellwood LC. Parental perceptions of stimulants for ADHD. J Dev Behav Pediatr. In press.
46. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.